AKESO

Akeso declined 2.61% to HK$93.2 today, driven by profit-taking following the recent rally. The morning session opened at 96.2 and rapidly declined to the intraday low of 92.25, with the afternoon session extending weakness to 92.15 before rebounding modestly to the close of 93.2. Recent clinical progress in oncology remains encouraging, with the HER3 ADC AK138D1 dosing the first patient in the Phase Ib/II NSCLC trial; multiple brokers maintain Buy ratings, and Nomura expects interim profitability of around RMB 46 million. Yet the company's recent earnings reveal persistent challenges: while revenue grew a robust 56.41% year-over-year in Q4, net loss stood at HK$301.9 million with a net margin of -33%, signaling significant path-to-profitability concerns. The stock has declined 17.74% year-to-date and sits nearly 48% below its 52-week high of HK$179, underscoring the tension between near-term clinical catalysts and valuation vis-à-vis current losses.

Akeso declined 2.64% to HK$96.00, driven primarily by profit-taking pressure following recent gains despite continued positive developments in pipeline and commercial momentum. The company dosed the first patient in Phase Ib/II trial of HER3 ADC AK138D1 for advanced non-small-cell lung cancer, while Nomura, SPDB, and UBS all issued or maintained buy ratings, with Nomura projecting interim pre-tax profit of approximately RMB 46M from this year onward. Q4 revenue surged to HK$914.5M with 56.41% year-over-year growth, demonstrating robust product commercialization across its portfolio, though net loss remained substantially negative at HK$301.9M with 105.68% year-over-year deterioration, reflecting sustained high-intensity R&D investment. On valuation positioning, the stock has pulled back 46.37% from its 52-week high of HK$179 and declined 15.27% year-to-date, while trading 19.7% above the 52-week low of HK$80.20. As an unprofitable biotech firm with negative earnings multiple, valuation pressures persist and require profitability realization to be fully resolved.

Akeso Biopharma closed at HK$98.60, down 0.9%, after morning surge to HK$100.70 was eroded by afternoon profit-taking. Multiple brokers—Nomura, SPDB, UBS—maintain buy ratings and anticipate H1 2026 profit swing, with cadonilimab and pipeline candidates advancing through trials. However, earnings paint a contradictory picture: Q4 revenue surged 56.4% y-o-y, yet net loss expanded to HK$302.8M with -33% net margin and EPS deteriorating 93.7%, distancing from Nomura's turnaround thesis. Year-to-date decline of 12.97%, trading 44.92% below the 52-week high of HK$179 and clearly below the 60-day average of HK$104.58 reflects base-building phase. If profitability inflection materializes in H2 as guided, valuation pressure may reverse.

Akeso Biopharma shares declined 3.2% to HK$99.5 today, driven by profit-taking pressure and persistent valuation concerns. The company recently announced updated overall survival data for ivonescimab (a PD-1/VEGF inhibitor) in international markets and initiated Phase II trials including AK146D1 combined with ivonescimab for advanced non-small-cell lung cancer and cadonilimab for perioperative gastric cancer treatment. However, these clinical catalysts appear largely priced into expectations. Q4 revenue reached HK$914.5 million, up 56.4% year-over-year, yet the company posted a net loss of HK$301.9 million with a net margin of -33.0%, reflecting heavy R&D spending. Shares are down 12.18% year-to-date and have retreated 44.41% from the 52-week high of HK$179, trading above the 20-day but below the 60-day moving average. While medical insurance reimbursement approval provides some support, the accompanying pricing pressure creates headwinds. Investors await evidence of the company's transition from clinical advancement toward commercial success.

Akeso Biopharma rose approximately 4% to HKD 102.8 today, driven primarily by recent clinical progress. AK146D1 combined with ivonescimab has advanced to Phase II dosing, while Cadonilimab (PD-1/CTLA-4) initiated Phase II trials in the U.S. for perioperative treatment of advanced gastric cancer. Q4 revenues surged 56.41% year-over-year to HKD 914.5 million, though the company remains unprofitable with net losses of HKD 301.9 million and a negative 33% net margin, reflecting commercialization investment pressure. The stock currently trades 42.57% below its 52-week high of HKD 179 and is down 9.27% year-to-date, holding above the 20-day moving average of HKD 95.4 but below the 60-day average of HKD 105.84. Recent favorable medical insurance policy developments provide tailwinds, yet the elevated 9.45x price-to-book ratio continues to limit valuation upside.